StockMacro
Menu

Merck

$133.72 +12% in 6 monthsMarket cap $329.7B

MRK on XNYS, Health Care, Merck & Co., Inc., job postings

Measures activity, not value. Not investment advice.

Profit fell 87% to $2.5B over 12 months even as revenue grew 4.9%.

  • WatchCompanies with layoff notices beat their sector by median 11.0 points historically

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).

Industry
Pharmaceutical preparations (Health Care)
Employees
75,000
Website
merck.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 2 Feb 2027 (an estimate: a year ago it reported on 3 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $18.1B, net income $5.1B.
Quarter to 31 Dec 2021: revenue –, net income $3.8BQuarter to 31 Mar 2022: revenue $15.9B, net income $4.3BQuarter to 31 Mar 2022: revenue $15.9B, net income $4.3BQuarter to 30 Jun 2022: revenue $14.6B, net income $3.9BQuarter to 30 Jun 2022: revenue $14.6B, net income $3.9BQuarter to 30 Sep 2022: revenue $15.0B, net income $3.2BQuarter to 30 Sep 2022: revenue $15.0B, net income $3.2BQuarter to 31 Dec 2022: revenue –, net income $3.0BQuarter to 31 Mar 2023: revenue $14.5B, net income $2.8BQuarter to 31 Mar 2023: revenue $14.5B, net income $2.8BQuarter to 30 Jun 2023: revenue $15.0B, net income -$6.0BQuarter to 30 Jun 2023: revenue $15.0B, net income -$6.0BQuarter to 30 Sep 2023: revenue $16.0B, net income $4.7BQuarter to 30 Sep 2023: revenue $16.0B, net income $4.7BQuarter to 31 Dec 2023: revenue $14.6B, net income -$1.2BQuarter to 31 Dec 2023: revenue $14.6B, net income -$1.2BQuarter to 31 Mar 2024: revenue $15.8B, net income $4.8BQuarter to 31 Mar 2024: revenue $15.8B, net income $4.8BQuarter to 30 Jun 2024: revenue $16.1B, net income $5.5BQuarter to 30 Jun 2024: revenue $16.1B, net income $5.5BQuarter to 30 Sep 2024: revenue $16.7B, net income $3.2BQuarter to 30 Sep 2024: revenue $16.7B, net income $3.2BQuarter to 31 Dec 2024: revenue $15.6B, net income $3.7BQuarter to 31 Dec 2024: revenue $15.6B, net income $3.7BQuarter to 31 Mar 2025: revenue $15.5B, net income $5.1BQuarter to 31 Mar 2025: revenue $15.5B, net income $5.1BQuarter to 30 Jun 2025: revenue $15.8B, net income $4.4BQuarter to 30 Jun 2025: revenue $15.8B, net income $4.4BQuarter to 30 Sep 2025: revenue $17.3B, net income $5.8BQuarter to 30 Sep 2025: revenue $17.3B, net income $5.8BQuarter to 31 Dec 2025: revenue $16.4B, net income $3.0BQuarter to 31 Dec 2025: revenue $16.4B, net income $3.0BQuarter to 31 Mar 2026: revenue $16.3B, net income -$4.2BQuarter to 31 Mar 2026: revenue $16.3B, net income -$4.2BQuarter to 30 Jun 2026: revenue $16.6B, net income -$1.3BQuarter to 30 Jun 2026: revenue $16.6B, net income -$1.3BQuarter to 30 Sep 2026: revenue $18.1B, net income $5.1BQuarter to 30 Sep 2026: revenue $18.1B, net income $5.1B
31 Dec 2021RevenueNet incomeNet losstallest bar $18.1B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$18.1B$5.1B
30 Jun 2026$16.6B-$1.3B
31 Mar 2026$16.3B-$4.2B
31 Dec 2025$16.4B$3.0B
30 Sep 2025$17.3B$5.8B
30 Jun 2025$15.8B$4.4B
31 Mar 2025$15.5B$5.1B
31 Dec 2024$15.6B$3.7B
30 Sep 2024$16.7B$3.2B
30 Jun 2024$16.1B$5.5B
31 Mar 2024$15.8B$4.8B
31 Dec 2023$14.6B-$1.2B
30 Sep 2023$16.0B$4.7B
30 Jun 2023$15.0B-$6.0B
31 Mar 2023$14.5B$2.8B
31 Dec 2022–$3.0B
30 Sep 2022$15.0B$3.2B
30 Jun 2022$14.6B$3.9B
31 Mar 2022$15.9B$4.3B
31 Dec 2021–$3.8B
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $67.4B $64.2B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +4.9% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $2.5B $19.0B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $0.98 $7.57
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 71.8% 77.2% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 3.6% 29.6% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 5.1% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $14.7B $13.0B
CashCash, cash equivalents and short-term investments on the latest balance sheet. $9.7B $18.2B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $53.8B $41.4B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $44.1B $23.2B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 1.2 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.21
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 134 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.9 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.5 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 7.3 2.0
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 2.5% 2.5%

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
MerckMRK (this company) $329.7B1344.9+4.9%3.6%
AbbvieABBV $505.9B48.97.7+11%15.7%
Abbott LaboratoriesABT $178.4B37.93.7+10%9.7%
Johnson & JohnsonJNJ $651.1B40.56.6+7.8%16.2%
PfizerPFE $156.2B38.72.5+1.3%6.3%
Vertex PharmaceuticalsVRTX $130.6B32.810.1+10%30.7%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$8.6M

bought $0, sold $8.6M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+4.3%

3,924 13F filers vs 3,763

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

78%

1.9B shares held by 13F filers (30 Sep 2026) of 2.5B outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.1%

26.6M shares sold short (30 Oct 2026) of 2.5B outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.4

26.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.8%

26.8M shares sold short in the report before, 26.6M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

34%

34% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 45%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

844

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+4.7%

$18.1B vs $17.3B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+5.4%

$1.0B vs $987.0M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$5.2M

the 12 months before: $155.2M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$11.4M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

142

the 12 months before: 430

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

106

106 articles in the last 7 days; its usual week has 9.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

106 articles in the last 7 days; its usual week has 9.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Page views 6,672, 1.5× a year earlier
  • Layoff notice 54 workers

Price $133.72 on 20 Nov 2026, +41% over 12 months (12-month range $94.97 to $156.45)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $79.3M in the last 12 months (the 12 months before: -$1.5M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 42 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $18.1B in the latest quarter, +4.7% on a year earlier.
Capital spending per quarter. Capital spending $1.0B in the latest quarter, +5.4% on a year earlier.
Institutional holders (13F filers). 3,924 13F filers reported holding it in the latest 13F quarter, +25% on a year earlier.
Federal obligations. Federal obligations: $2.7M published in the last 12 months, -54% on the 12 months before.
Lobbying spend. Lobbying spend: $11.4M published in the last 12 months, +1.6% on the 12 months before.
Workers in WARN layoff notices. Workers in WARN layoff notices: 346 published in the last 12 months, +53% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
18 Nov 20268-K and other filingsDirector Thomas H. Glocer gave notice of his intention to retire from the Board as of the 2027 Annual Meeting of Shareholders
13 Oct 20268-K and other filingsDirector or officer change
13 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Oct 2026Lobbying filingnew lobbying registration (THE WASHINGTON TAX & PUBLIC POLICY GROUP)
1 Oct 2026WARN layoff noticeMerck & Co, 54 workers, Rahway, NJ
1 Oct 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 54)
25 Aug 2026Sharp changeWikipedia attention spike: wikipedia attention spike, 6,672 vs usual 3,652.50 (2026-08-17..2026-08-23); 1.5x the same week a year earlier
1 Jul 2026WARN layoff noticeMerck & Co, 88 workers, Rahway, NJ
1 Jul 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 88)
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 267 vs usual 124 (2025-12-31); 2.9x the same period a year earlier
21 Jan 2026Lobbying filinglobbying engagement terminated (HARBINGER STRATEGIES, LLC)
1 Dec 2025WARN layoff noticeMerck, 204 workers, Rahway, NJ
1 Dec 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 204)
2 Sep 2025Lobbying filingnew lobbying registration (BALLARD PARTNERS)
1 Sep 2025WARN layoff noticeMerck & Co., 58 workers, Rahway, NJ
1 Sep 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 58)
29 Jul 20258-K and other filingsRestructuring costs announced
15 Jul 2025Lobbying filingnew lobbying registration (B HALL STRATEGIES, LLC)
6 May 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 1.3B vs usual 919.5M (2025-03-31); 1.5x the same period a year earlier
18 Apr 2025Lobbying filinglobbying engagement terminated (CAPITOL COUNSEL LLC)
14 Mar 2025WARN layoff noticeMerck & Co., Inc., 163 workers, Montour, PA
14 Mar 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 163)
31 Jan 2025Lobbying filingnew lobbying registration (HARBINGER STRATEGIES, LLC)
1 Jan 2025WARN layoff noticeMerck & Co., Inc., 5 workers, Montgomery, PA
1 Jan 2025Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 5)
22 Nov 20248-K and other filingsDirector or officer change
22 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Oct 2024Sharp changeFirst federal award: first federal award: MERCK SHARP & DOHME LLC: new Department of Health and Human Services contract 75A50124C00057 ($153,000,000)
20 Feb 20248-K and other filingsDirector or officer change
1 Feb 20248-K and other filingsRestructuring costs announced
28 Nov 20238-K and other filingsDirector or officer change
28 Nov 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Mar 2023Lobbying filingnew lobbying registration (FORBES-TATE)
14 Feb 2023Sharp changeMany funds opening a new position: many funds opening a new position, 193 vs usual 95 (2022-12-31); 1.8x the same period a year earlier
27 Oct 20228-K and other filingsDirector or officer change
27 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 May 2022Sharp changeQuarterly revenue change: quarterly revenue change, 15.9B vs usual 12.1B (2022-03-31); 1.3x the same period a year earlier
21 Apr 2022Lobbying filinglobbying engagement terminated (SPLITOAK STRATEGIES LLC)
20 Jan 2022Lobbying filinglobbying engagement terminated (PUBLIC STRATEGIES WASHINGTON, INC.)
20 Jan 2022Lobbying filinglobbying engagement terminated (THE KPM GROUP DC LLC)
20 Jan 2022Lobbying filinglobbying engagement terminated (CONAWAY GRAVES GROUP, LLC)
18 Jan 2022Lobbying filinglobbying engagement terminated (in-house)
13 Jan 2022Lobbying filinglobbying engagement terminated (BGR GOVERNMENT AFFAIRS)
Insider net buying (open market)
Month from 1 Nov 2022: -$291.3M published
Month from 1 Jan 2023: -$9.4M published
Month from 1 Feb 2023: -$9.5M published
Month from 1 Apr 2023: -$31.9M published
Month from 1 May 2023: -$27.7M published
Month from 1 Jul 2023: $41K published
Month from 1 Aug 2023: -$948K published
Month from 1 Nov 2023: -$4.8M published
Month from 1 Feb 2024: -$51.6M published
Month from 1 Feb 2025: $141K published
Month from 1 Apr 2025: -$353K published
Month from 1 Nov 2025: -$1.3M published
Month from 1 Feb 2026: -$40.7M published
Month from 1 Aug 2026: -$30.0M published
Month from 1 Nov 2026: -$8.6M published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 42 published
Revenue per quarter
Quarter ended 31 Mar 2022: $15.9B, +32% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $14.6B, +28% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $15.0B, +14% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $14.5B, -8.9% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $15.0B, +3.0% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $16.0B, +6.7% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $14.6B; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $15.8B, +8.9% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $16.1B, +7.2% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $16.7B, +4.4% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $15.6B, +6.8% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $15.5B, -1.6% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $15.8B, -1.9% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $17.3B, +3.7% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $16.4B, +5.0% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $16.3B, +4.9% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $16.6B, +5.1% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $18.1B, +4.7% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $984.0M, -13% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.1B; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $1.1B; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $1.0B, +2.3% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $965.0M, -15% on a year earlier; public on 8 Aug 2023
Quarter ended 30 Sep 2023: $902.0M, -20% on a year earlier; public on 4 Nov 2023
Quarter ended 31 Dec 2023: $989.0M; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $861.0M, -14% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $791.0M, -18% on a year earlier; public on 6 Aug 2024
Quarter ended 30 Sep 2024: $783.0M, -13% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $937.0M, -5.3% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $1.3B, +54% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $764.0M, -3.4% on a year earlier; public on 6 Aug 2025
Quarter ended 30 Sep 2025: $987.0M, +26% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $1.0B, +10% on a year earlier; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $991.0M, -25% on a year earlier; public on 5 May 2026
Quarter ended 30 Jun 2026: $893.0M, +17% on a year earlier; public on 8 Aug 2026
Quarter ended 30 Sep 2026: $1.0B, +5.4% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,554; public on 14 Feb 2022
31 Mar 2022 report: 2,751; public on 16 May 2022
30 Jun 2022 report: 2,818; public on 15 Aug 2022
30 Sep 2022 report: 2,729; public on 14 Nov 2022
31 Dec 2022 report: 2,933; public on 14 Feb 2023
31 Mar 2023 report: 2,954; public on 15 May 2023
30 Jun 2023 report: 2,984; public on 14 Aug 2023
30 Sep 2023 report: 2,954; public on 14 Nov 2023
31 Dec 2023 report: 3,152; public on 14 Feb 2024
31 Mar 2024 report: 3,324; public on 15 May 2024
30 Jun 2024 report: 3,330; public on 14 Aug 2024
30 Sep 2024 report: 3,284; public on 14 Nov 2024
31 Dec 2024 report: 3,368; public on 14 Feb 2025
31 Mar 2025 report: 3,278; public on 15 May 2025
30 Jun 2025 report: 3,177; public on 14 Aug 2025
30 Sep 2025 report: 3,149; public on 14 Nov 2025
31 Dec 2025 report: 3,466; public on 17 Feb 2026
31 Mar 2026 report: 3,670; public on 15 May 2026
30 Jun 2026 report: 3,763; public on 14 Aug 2026
30 Sep 2026 report: 3,924; public on 16 Nov 2026
Federal obligations
Month from 1 Jan 2024: $0.0 published
Month from 1 Feb 2024: $96K published
Month from 1 Mar 2024: $140K published
Month from 1 Apr 2024: $226K published
Month from 1 May 2024: $41K published
Month from 1 Jun 2024: $140K published
Month from 1 Jul 2024: $1.4M published
Month from 1 Aug 2024: -$117K published
Month from 1 Sep 2024: $472K published
Month from 1 Oct 2024: $153.3M published
Month from 1 Nov 2024: $290K published
Month from 1 Dec 2024: $137K published
Month from 1 Jan 2025: -$180K published
Month from 1 Feb 2025: $438K published
Month from 1 Mar 2025: $267K published
Month from 1 Apr 2025: -$59K published
Month from 1 May 2025: $31K published
Month from 1 Jun 2025: $106K published
Month from 1 Jul 2025: $487K published
Month from 1 Aug 2025: $4.5M published
Month from 1 Sep 2025: $175K published
Month from 1 Oct 2025: $140K published
Month from 1 Nov 2025: -$177K published
Month from 1 Dec 2025: -$112K published
Month from 1 Jan 2026: $179K published
Month from 1 Feb 2026: $29K published
Month from 1 Mar 2026: $218K published
Month from 1 Apr 2026: -$228K published
Month from 1 May 2026: $471K published
Month from 1 Jun 2026: $49K published
Month from 1 Jul 2026: $0 published
Month from 1 Aug 2026: $122K published
Month from 1 Sep 2026: $2.3M published
Month from 1 Oct 2026: -$305K published
Month from 1 Nov 2026: -$21K published
Lobbying spend
Quarter from 1 Jan 2022: $1.6M published
Quarter from 1 Apr 2022: $2.2M published
Quarter from 1 Jul 2022: $2.7M published
Quarter from 1 Oct 2022: $1.1M published
Quarter from 1 Jan 2023: $2.5M published
Quarter from 1 Apr 2023: $3.0M published
Quarter from 1 Jul 2023: $3.1M published
Quarter from 1 Oct 2023: $2.2M published
Quarter from 1 Jan 2024: $2.0M published
Quarter from 1 Apr 2024: $2.3M published
Quarter from 1 Jul 2024: $3.1M published
Quarter from 1 Oct 2024: $2.2M published
Quarter from 1 Jan 2025: $1.9M published
Quarter from 1 Apr 2025: $2.6M published
Quarter from 1 Jul 2025: $5.1M published
Quarter from 1 Oct 2025: $1.7M published
Quarter from 1 Jan 2026: $2.1M published
Quarter from 1 Apr 2026: $4.3M published
Quarter from 1 Jul 2026: $2.4M published
Quarter from 1 Oct 2026: $2.6M published
Workers in WARN layoff notices
Month from 1 Jan 2025: 5 published
Month from 1 Mar 2025: 163 published
Month from 1 Sep 2025: 58 published
Month from 1 Dec 2025: 204 published
Month from 1 Jul 2026: 88 published
Month from 1 Oct 2026: 54 published

What is unusual now

  • Made public in the last 90 days: it drew 6,672 Wikipedia page views in the week of 17 Aug 2026, 1.5× the same week last year; it also filed a WARN layoff notice covering 54 workers within 30 days (Rahway, NJ).
  • Wikipedia attention spike: drew 6,672 Wikipedia page views in the week of 17 Aug 2026, 1.5× the same week last year Public on 25 Aug 2026.
  • WARN layoff notice: filed a WARN layoff notice covering 54 workers within 30 days (Rahway, NJ) Public on 1 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $79.3M in the last 12 months (the 12 months before: -$1.5M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $8.6M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Richard R. DeLucaEVP&Pres, Merck Animal HeallthSellafter exercising options58,185$148.01$8.6MForm 4
13 Aug 2026Chirfi GuindoEVP, Access, Policy & CommsSell10,000$135.00$1.4MForm 4
13 Aug 2026Jennifer ZacharyEVP, General CounselSellafter exercising options80,315$133.46$10.7MForm 4
12 Aug 2026Richard R. DeLucaEVP&Pres, Merck Animal HeallthSell45,320$131.12$5.9MForm 4
10 Aug 2026Richard R. DeLucaEVP&Pres, Merck Animal HeallthSell6,050$130.37$789KForm 4
7 Aug 2026David Michael WilliamsEVP,Chief Info&Digital OfficerSellafter exercising options52,847$128.77$6.8MForm 4
7 Aug 2026Chirfi GuindoEVP, Access, Policy & CommsSell15,000$131.00$2.0MForm 4
7 Aug 2026David R. MaraldoEVP & Pres. MMDSellafter exercising options18,706$128.72$2.4MForm 4

3,924 institutions reported shares at the end of Q3 2026, 78% of the shares outstanding; 256 opened a position, 104 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.228.1M9.25%$33.1B+1.1M+0.5%
Vanguard Capital Management LLC161.5M6.55%$23.5B+190K+0.1%
State Street Corp121.4M4.93%$17.7B+1.0M+0.8%
Wellington Management Group LLP71.7M2.91%$10.4B-14.6M-17%
Vanguard Portfolio Management LLC68.1M2.76%$9.9B+371K+0.5%
Geode Capital Management, LLC61.6M2.50%$8.9B+821K+1.4%
Charles Schwab Investment Management Inc50.8M2.06%$7.4B-3.5M-6.5%
Morgan Stanley48.2M1.96%$7.0B-407K-0.8%
FMR LLC (Fidelity)46.2M1.87%$6.7B+782K+1.7%
JPMorgan Chase & Co43.1M1.75%$6.4B-771K-1.8%

Federal contracts

All 2 federal contracts

1 new award in 12 months, $1.6M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
14 Sep 2026Department of Health and Human ServicesCenters for Disease Control and Prevention$1.6MSTOCKPILE STORAGE AND ROTATION EO 14398USAspending
27 Sep 2024Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$153.0Mup to $174.6MERVEBO PROCUREMENTUSAspending

Company events

All 22 company events

In 12 months: 2 director or officer changes. Results releases and routine reports are left out.

FiledWhat happenedSource
18 Nov 2026Director Thomas H. Glocer gave notice of his intention to retire from the Board as of the 2027 Annual Meeting of Shareholders8-K
13 Oct 2026Director or officer change8-K
29 Jul 2025Restructuring costs announced8-K
22 Nov 2024Director or officer changeSame filing: changed its bylaws or fiscal year8-K
20 Feb 2024Director or officer change8-K
1 Feb 2024Restructuring costs announced8-K
28 Nov 2023Director or officer change8-K
27 Oct 2022Director or officer change8-K

844 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 11%, Marketing & communications 5%, Operations & administration 5%, ML / AI 4%.

PostedJobLocation
20 Nov 2026or earlierAnimal Health Swine Customer Team ManagerJPN - Tokyo - Chiyoda
20 Nov 2026or earlierDir, Policy/Govern. Relations Health PolicyLegal, policy & complianceJPN - Tokyo - Chiyoda
20 Nov 2026or earlierAnimal Health, Regulatory AffairsLegal, policy & complianceJPN - Tokyo - Chiyoda
20 Nov 2026or earlierAnimal Health Companion Animal Customer ConsultantNot stated
20 Nov 2026or earlierUtilities Facilities Management InternFacilities & constructionSGP - Singapore - Singapore (70 Tuas West Dr)
20 Nov 2026or earlier(Sr.) Manager, Immunology, Medical AffairsNot stated
20 Nov 2026or earlierAuszubildender (m/w/d) zum PharmakantenDEU - Niedersachsen - Friesoythe
20 Nov 2026or earlierAssoc. Dir, Marketing ONCMarketing & communicationsJPN - Tokyo - Chiyoda

Reported lobbying spend: $2.6M in Q3 2026, $2.4M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Sep 2026NewThe Washington Tax & Public Policy Groupfor Merck & Co., IncIssues related to corporate and international taxTaxationFiling
31 Dec 2025EndedHarbinger Strategies, LLCfor Merck & Co., Inc.Issues related to international tax policy.TaxationFiling
21 Jul 2025NewBallard Partnersfor Merck Sharp & Dohme LLCGuidance and advocacy related to drug pricing and tariffs.Pharmacy, TARFiling
1 Apr 2025NewB Hall Strategies, LLCfor Tiber Creek Group On Behalf Of Merck & Co., Inc.Issues related to drug pricing and reimbursement of prescription drugs; Issues related to Medicare Part D and Part B Pricing Reform.Medicare/MedicaidFiling
28 Feb 2025EndedCapitol Counsel LLCfor Merck & Company, Inc.Not statedFiling
13 Jan 2025NewHarbinger Strategies, LLCfor Merck & Co., Inc.Issues related to international tax policy.TaxationFiling
24 Jan 2023NewForbes-Tatefor Merck Animal HealthIssues related to health products and technology for animals and aquaculture.ANI, Agriculture, MAR, NATFiling
1 Jan 2022EndedSplitoak Strategies LLCfor Acceleron Pharma, IncHR 5376, Build Back Better Act-impact on rare disease research; HR 5376, Build Back Better Act-importance of the Orphan Drug Tax Credit for rare diseasesMedicare/Medicaid, Health issues, TaxationFiling

Layoff notices

All 19 layoff notices

2 notices in 12 months covering 142 workers. State WARN notices.

NoticeSiteWorkersJobs endSource
1 Sep 2026Merck & CoRahway, NJ5411 Dec 2026Notice
1 Jun 2026Merck & CoRahway, NJ884 Sep 2026Notice
1 Nov 2025MerckRahway, NJ20420 Feb 2026Notice
1 Aug 2025Merck & Co.Rahway, NJ5814 Nov 2025Notice
14 Mar 2025Merck & Co., Inc.Montour, PA163Not statedclosureNotice
1 Jan 2025Merck & Co., Inc.Montgomery, PA515 Mar 2024layoffNotice
1 Sep 2016MerckKenilworth, NJ6414 Nov 2016Notice
1 Jan 2015Merck - BranchburgBranchburg, NJ17216 Mar 2015Notice

The 5 newest of 812 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 18 Nov 2026Filings record

    Director Thomas H. Glocer gave notice of his intention to retire from the Board as of the 2027 Annual Meeting of Shareholders

  2. 13 Nov 2026Institutional holdings record

    MARSHALL WACE, LLP opened a $404.0M position (2026Q3 13F)

  3. 13 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 13 Oct 2026Filings record

    Director or officer change

  5. 8 Oct 2026Lobbying record

    MERCK & CO., INC: new lobbying registration (THE WASHINGTON TAX & PUBLIC POLICY GROUP) (dated 1 Sep 2026)

  6. 1 Oct 2026Layoff notices change

    filed a WARN layoff notice covering 54 workers within 30 days (Rahway, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    54
    Window
    1 Sep 2026 to 1 Oct 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  7. 1 Oct 2026Layoff notices record

    WARN notice: Merck & Co, 54 workers, Rahway, NJ (dated 1 Sep 2026)

  8. 20 Sep 2026Government contracts record

    MERCK SHARP & DOHME LLC: new Department of Health and Human Services contract 75D30126F00001 ($1.6M) (dated 14 Sep 2026)

  9. 25 Aug 2026Attention change

    drew 6,672 Wikipedia page views in the week of 17 Aug 2026, 1.5× the same week last year.

    Same week last year: 4,572; its normal week is 3,652.

    See the evidence
    This period
    6,672 (the week of 17 Aug 2026)
    Normal week (median of 26 earlier)
    3,652
    Typical spread (median absolute deviation)
    304
    How far from its usual level
    +6.7
    Same week last year
    4,572
    History used
    2,791 days
    2026-02-16: 3,8242026-02-23: 4,6172026-03-02: 3,7702026-03-09: 3,4692026-03-16: 3,3392026-03-23: 3,7352026-03-30: 3,4312026-04-06: 3,2942026-04-13: 4,1972026-04-20: 3,8772026-04-27: 4,0832026-05-04: 3,8232026-05-11: 3,7432026-05-18: 3,9462026-05-25: 3,4492026-06-01: 4,4482026-06-08: 3,5982026-06-15: 3,0332026-06-22: 3,8342026-06-29: 3,2642026-07-06: 3,1932026-07-13: 3,7072026-07-20: 3,0532026-07-27: 3,2872026-08-03: 3,2942026-08-10: 3,1192026-08-17: 6,672
    the week of 17 Aug 202626 earlier weeksnormal: 3,652

    Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.

    Check it at the source: Wikimedia page view statistics.

  10. 1 Jul 2026Layoff notices change

    filed a WARN layoff notice covering 88 workers within 30 days (Rahway, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    88
    Window
    1 Jun 2026 to 1 Jul 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  11. 1 Jul 2026Layoff notices record

    WARN notice: Merck & Co, 88 workers, Rahway, NJ (dated 1 Jun 2026)

  12. 17 Feb 2026Institutional holdings change

    saw 267 13F filers open a new position in the quarter ended 31 Dec 2025, 2.9× the same quarter last year.

    Same quarter last year: 93; its normal quarter is 124.

    See the evidence
    This period
    267 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    124
    Typical spread (median absolute deviation)
    15.5
    How far from its usual level
    +6.2
    Same quarter last year
    93
    History used
    4,475 days
    2023-12-31: 1172024-03-31: 1732024-06-30: 1232024-09-30: 842024-12-31: 932025-03-31: 1252025-06-30: 1272025-09-30: 1482025-12-31: 267
    the quarter ended 31 Dec 20258 earlier quartersnormal: 124

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 30 Jan 2026Institutional holdings record

    JENNISON ASSOCIATES LLC opened a $585.0M position (2025Q4 13F)

  14. 21 Jan 2026Lobbying record

    MERCK & CO., INC.: lobbying engagement terminated (HARBINGER STRATEGIES, LLC) (dated 31 Dec 2025)

  15. 1 Dec 2025Layoff notices change

    filed a WARN layoff notice covering 204 workers within 30 days (Rahway, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    204
    Window
    1 Nov 2025 to 1 Dec 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  16. 1 Dec 2025Layoff notices record

    WARN notice: Merck, 204 workers, Rahway, NJ (dated 1 Nov 2025)

  17. 2 Sep 2025Lobbying record

    MERCK SHARP & DOHME LLC: new lobbying registration (BALLARD PARTNERS) (dated 21 Jul 2025)

  18. 1 Sep 2025Layoff notices change

    filed a WARN layoff notice covering 58 workers within 30 days (Rahway, NJ).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    58
    Window
    2 Aug 2025 to 1 Sep 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  19. 1 Sep 2025Layoff notices record

    WARN notice: Merck & Co., 58 workers, Rahway, NJ (dated 1 Aug 2025)

  20. 29 Jul 2025Filings record

    Restructuring costs announced

  21. 15 Jul 2025Lobbying record

    TIBER CREEK GROUP ON BEHALF OF MERCK & CO., INC.: new lobbying registration (B HALL STRATEGIES, LLC) (dated 1 Apr 2025)

  22. 6 May 2025Financials change

    spent $1.3B on capital projects in the quarter ended 31 Mar 2025, 1.5× the same quarter last year.

    Same quarter last year: $861.0M; its normal quarter is $919.5M.

    See the evidence
    This period
    $1.3B (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    $919.5M
    Typical spread (median absolute deviation)
    $64.0M
    How far from its usual level
    +4.3
    Same quarter last year
    $861.0M
    History used
    6,026 days
    2023-03-31: $1.0B2023-06-30: $965.0M2023-09-30: $902.0M2023-12-31: $989.0M2024-03-31: $861.0M2024-06-30: $791.0M2024-09-30: $783.0M2024-12-31: $937.0M2025-03-31: $1.3B
    the quarter ended 31 Mar 20258 earlier quartersnormal: $919.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  23. 18 Apr 2025Lobbying record

    MERCK & COMPANY, INC.: lobbying engagement terminated (CAPITOL COUNSEL LLC) (dated 28 Feb 2025)

  24. 14 Mar 2025Layoff notices change

    filed a WARN layoff notice covering 163 workers within 30 days.

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    163
    Window
    12 Feb 2025 to 14 Mar 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  25. 14 Mar 2025Layoff notices record

    WARN notice (closure): Merck & Co., Inc., 163 workers, Montour, PA

  26. 8 Feb 2025Insiders record

    BAKER DOUGLAS M JR (director) bought 15,000 shares of MRK ($1.3M) (dated 7 Feb 2025)

  27. 8 Feb 2025Insiders record

    THULIN INGE G (director) bought 2,833 shares of MRK ($250,000) (dated 7 Feb 2025)

  28. 31 Jan 2025Lobbying record

    MERCK & CO., INC.: new lobbying registration (HARBINGER STRATEGIES, LLC) (dated 13 Jan 2025)

  29. 1 Jan 2025Layoff notices change

    filed a WARN layoff notice covering 5 workers within 30 days.

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    5
    Window
    2 Dec 2024 to 1 Jan 2025

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  30. 1 Jan 2025Layoff notices record

    WARN notice (layoff): Merck & Co., Inc., 5 workers, Montgomery, PA

  31. 22 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 22 Nov 2024Filings record

    Director or officer change

  33. 14 Nov 2024Institutional holdings record

    HARRIS ASSOCIATES L P opened a $334.0M position (2024Q3 13F)

  34. 3 Oct 2024Government contracts change

    won its first federal award in our data, a $153.0M Department of Health and Human Services contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  35. 3 Oct 2024Government contracts record

    MERCK SHARP & DOHME LLC: new Department of Health and Human Services contract 75A50124C00057 ($153.0M) (dated 27 Sep 2024)

  36. 20 Feb 2024Filings record

    Director or officer change

  37. 1 Feb 2024Filings record

    Restructuring costs announced

  38. 28 Nov 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 28 Nov 2023Filings record

    Director or officer change

  40. 1 Jul 2023Insiders record

    Romanelli Joseph (President, Human Health Int?l) bought 409 shares of MRK ($44,336) (dated 30 Jun 2023)

Showing the newest 40 of 145 entries; narrow the window or the kind of data to see older ones.

Not listed: 248 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Articles about this company

The latest 2 that name MRK

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000310158
Ticker
MRK
Domain
merck.com
Employer name
Merck & Co. Inc., merck research laboratories massachusetts, Merck Sharp & Dohme LLC, MRL San Francisco, LLC and 2 more (6 unverified)
Fein
22-1261880, 81-3649169 (2 unverified)
Hq location
NJ|RAHWAY|07065 (1 unverified)
Lobbying client
acceleron pharma, cubist pharmaceuticals, merck, merck sharp and dohme and 2 more
Name
7728026 Canada Inc, Abceutics, Inc, Abmaxis Inc, Acceleron Pharma Inc and 326 more
Uei
GYXFTAF6L3W4
Wikidata
Q247489
Wikipedia
Merck & Co.
  • DOL H-1B labor condition applications and PERM certifications100 data points27 Jul 2020 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)127 records, 279 data points30 Dec 1899 to 30 Sep 2026
  • SEC Form 13F institutional holdings14 records, 481 data points30 Jun 2013 to 13 Nov 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)124 records3 Feb 2016 to 18 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1102 data points31 Dec 2006 to 31 Oct 2026
  • SEC Form 4 insider transactions149 records, 412 data points14 Apr 2016 to 16 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards2 records, 456 data points12 Jan 2024 to 28 Oct 2026
  • WARN layoff notices (state labor agencies)19 records, 57 data points7 Jul 1997 to 1 Sep 2026
  • Wikipedia pageviews2881 data points1 Jan 2019 to 20 Nov 2026